We are Fulfilling Unmet Needs in Pulmonary Medicine. Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the Company is uniquely positioned to fulfill unmet needs in pulmonary medicine. Our corporate strategy includes the following: • Continued development of proprietary respiratory disease therapies • Pursue regulatory pathways that reduce the time, costs and risks associated with product development • Conservation of capital for proprietary product development through the outsourcing of late stage clinical and commercial scale manufacturing • Deployment of a specialized sales and marketing force to meet the unique needs of pulmonologists in the United States • Out-licensing technology and intellectual property assets for applications that lie outside the company's strategic interests and core expertise
Hayward, US
16 (est)-11%
Aradigm is headquartered in Hayward, US

Key People at Aradigm

Igor Gonda

Igor Gonda

President & Chief Executive Officer
Nancy Pecota

Nancy Pecota

Chief Financial Officer

Aradigm Locations

Hayward, US

Aradigm Metrics

Aradigm Summary

Market capitalization

$26.3 M

Closing share price

Aradigm's current market capitalization is $26.3 M.

Aradigm Financials

Aradigm's revenue is $23.4 M in FY, 2015 which is 30.19% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


$9.72 M$33.6 M$23.4 M

Operating income

$-19.9 M$-3.86 M$-17.2 M

Operating expense total

$29.6 M$37.4 M$40.6 M

Net Income

$-21.6 M$4.65 M$-17.2 M

Operating cash flow

$40.7 M$-141 K$-16.5 M

    Aradigm Market Value History

    We estimate that Aradigm's current employees are approximately 31% female and 69% male.

    Aradigm Company Life

    You may also be interested in